Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 125

1.

Acceptability of self-sampling and human papillomavirus testing among non-attenders of cervical cancer screening programs in El Salvador.

Maza M, Melendez M, Masch R, Alfaro K, Chacon A, Gonzalez E, Soler M, Conzuelo-Rodriguez G, Gage JC, Alonzo TA, Castle PE, Felix JC, Cremer M.

Prev Med. 2018 Jun 26;114:149-155. doi: 10.1016/j.ypmed.2018.06.017. [Epub ahead of print]

2.

Automated Cervical Screening and Triage, Based on HPV Testing and Computer-Interpreted Cytology.

Yu K, Hyun N, Fetterman B, Lorey T, Raine-Bennett TR, Zhang H, Stamps RE, Poitras NE, Wheeler W, Befano B, Gage JC, Castle PE, Wentzensen N, Schiffman M.

J Natl Cancer Inst. 2018 Apr 11. doi: 10.1093/jnci/djy044. [Epub ahead of print]

PMID:
29659930
3.

Validation of a Human Papillomavirus (HPV) DNA Cervical Screening Test That Provides Expanded HPV Typing.

Demarco M, Carter-Pokras O, Hyun N, Castle PE, He X, Dallal CM, Chen J, Gage JC, Befano B, Fetterman B, Lorey T, Poitras N, Raine-Bennett TR, Wentzensen N, Schiffman M.

J Clin Microbiol. 2018 Apr 25;56(5). pii: e01910-17. doi: 10.1128/JCM.01910-17. Print 2018 May.

PMID:
29491018
4.

Clinical Outcomes after Conservative Management of Cervical Intraepithelial Neoplasia Grade 2 (CIN2) in Women Ages 21-39 Years.

Silver MI, Gage JC, Schiffman M, Fetterman B, Poitras NE, Lorey T, Cheung LC, Katki HA, Locke A, Kinney WK, Castle PE.

Cancer Prev Res (Phila). 2018 Mar;11(3):165-170. doi: 10.1158/1940-6207.CAPR-17-0293. Epub 2018 Feb 5.

PMID:
29437696
5.

Epidemiologic Evidence That Excess Body Weight Increases Risk of Cervical Cancer by Decreased Detection of Precancer.

Clarke MA, Fetterman B, Cheung LC, Wentzensen N, Gage JC, Katki HA, Befano B, Demarco M, Schussler J, Kinney WK, Raine-Bennett TR, Lorey TS, Poitras NE, Castle PE, Schiffman M.

J Clin Oncol. 2018 Apr 20;36(12):1184-1191. doi: 10.1200/JCO.2017.75.3442. Epub 2018 Jan 22.

PMID:
29356609
6.

Effects of Maintenance on Quality of Performance of Cryotherapy Devices for Treatment of Precancerous Cervical Lesions.

Maza M, Figueroa R, Laskow B, Juárez A, Alfaro K, Alonzo TA, Felix JC, Gage JC, Cremer M.

J Low Genit Tract Dis. 2018 Jan;22(1):47-51. doi: 10.1097/LGT.0000000000000359.

PMID:
29271857
7.

Challenges in risk estimation using routinely collected clinical data: The example of estimating cervical cancer risks from electronic health-records.

Landy R, Cheung LC, Schiffman M, Gage JC, Hyun N, Wentzensen N, Kinney WK, Castle PE, Fetterman B, Poitras NE, Lorey T, Sasieni PD, Katki HA.

Prev Med. 2018 Jun;111:429-435. doi: 10.1016/j.ypmed.2017.12.004. Epub 2017 Dec 6.

8.

Effect of Several Negative Rounds of Human Papillomavirus and Cytology Co-testing on Safety Against Cervical Cancer: An Observational Cohort Study.

Castle PE, Kinney WK, Xue X, Cheung LC, Gage JC, Zhao FH, Fetterman B, Poitras NE, Lorey TS, Wentzensen N, Katki HA, Schiffman M.

Ann Intern Med. 2018 Jan 2;168(1):20-29. doi: 10.7326/M17-1609. Epub 2017 Nov 28.

PMID:
29181509
9.

Relative Performance of HPV and Cytology Components of Cotesting in Cervical Screening.

Schiffman M, Kinney WK, Cheung LC, Gage JC, Fetterman B, Poitras NE, Lorey TS, Wentzensen N, Befano B, Schussler J, Katki HA, Castle PE.

J Natl Cancer Inst. 2018 May 1;110(5):501-508. doi: 10.1093/jnci/djx225.

PMID:
29145648
10.

Risk of skin cancer among patients with myotonic dystrophy type 1 based on primary care physician data from the U.K. Clinical Practice Research Datalink.

Wang Y, Pfeiffer RM, Alsaggaf R, Meeraus W, Gage JC, Anderson LA, Bremer RC, Nikolenko N, Lochmuller H, Greene MH, Gadalla SM.

Int J Cancer. 2018 Mar 15;142(6):1174-1181. doi: 10.1002/ijc.31143. Epub 2017 Nov 20.

PMID:
29114849
11.

Diagnosis of Cervical Precancers by Endocervical Curettage at Colposcopy of Women With Abnormal Cervical Cytology.

Liu AH, Walker J, Gage JC, Gold MA, Zuna R, Dunn ST, Schiffman M, Wentzensen N.

Obstet Gynecol. 2017 Dec;130(6):1218-1225. doi: 10.1097/AOG.0000000000002330.

PMID:
29112672
12.

ASCCP Colposcopy Standards: Risk-Based Colposcopy Practice.

Wentzensen N, Schiffman M, Silver MI, Khan MJ, Perkins RB, Smith KM, Gage JC, Gold MA, Conageski C, Einstein MH, Mayeaux EJ Jr, Waxman AG, Huh WK, Massad LS.

J Low Genit Tract Dis. 2017 Oct;21(4):230-234. doi: 10.1097/LGT.0000000000000334.

PMID:
28953111
13.

Evidence-Based Consensus Recommendations for Colposcopy Practice for Cervical Cancer Prevention in the United States.

Wentzensen N, Massad LS, Mayeaux EJ Jr, Khan MJ, Waxman AG, Einstein MH, Conageski C, Schiffman MH, Gold MA, Apgar BS, Chelmow D, Choma KK, Darragh TM, Gage JC, Garcia FAR, Guido RS, Jeronimo JA, Liu A, Mathews CA, Mitchell MM, Moscicki AB, Novetsky AP, Papasozomenos T, Perkins RB, Silver MI, Smith KM, Stier EA, Tedeschi CA, Werner CL, Huh WK.

J Low Genit Tract Dis. 2017 Oct;21(4):216-222. doi: 10.1097/LGT.0000000000000322.

PMID:
28953109
14.

Outcomes in Women With Cytology Showing Atypical Squamous Cells of Undetermined Significance With vs Without Human Papillomavirus Testing.

Cuzick J, Myers O, Lee JH, Shi Y, Gage JC, Hunt WC, Robertson M, Wheeler CM; New Mexico HPV Pap Registry Steering Committee.

JAMA Oncol. 2017 Oct 1;3(10):1327-1334. doi: 10.1001/jamaoncol.2017.1040.

15.

Why does cervical cancer occur in a state-of-the-art screening program?

Castle PE, Kinney WK, Cheung LC, Gage JC, Fetterman B, Poitras NE, Lorey TS, Wentzensen N, Befano B, Schussler J, Katki HA, Schiffman M.

Gynecol Oncol. 2017 Sep;146(3):546-553. doi: 10.1016/j.ygyno.2017.06.003. Epub 2017 Jun 10.

PMID:
28606721
16.

Assessment of a New Lower-Cost Real-Time PCR Assay for Detection of High-Risk Human Papillomavirus: Useful for Cervical Screening in Limited-Resource Settings?

Fokom Domgue J, Schiffman M, Wentzensen NH, Gage JC, Castle PE, Raine-Bennett TR, Fetterman B, Lorey T, Poitras NE, Befano B, Xie Y, Miachon LS, Dean M.

J Clin Microbiol. 2017 Aug;55(8):2348-2355. doi: 10.1128/JCM.00492-17. Epub 2017 May 17.

17.

Discovery and validation of candidate host DNA methylation markers for detection of cervical precancer and cancer.

Clarke MA, Luhn P, Gage JC, Bodelon C, Dunn ST, Walker J, Zuna R, Hewitt S, Killian JK, Yan L, Miller A, Schiffman M, Wentzensen N.

Int J Cancer. 2017 Aug 15;141(4):701-710. doi: 10.1002/ijc.30781. Epub 2017 May 26.

PMID:
28500655
18.

Cervical cancer prevention in El Salvador (CAPE)-An HPV testing-based demonstration project: Changing the secondary prevention paradigm in a lower middle-income country.

Maza M, Alfaro K, Garai J, Velado MM, Gage JC, Castle PE, Felix J, Luciani S, Campos N, Kim J, Masch R, Cremer M.

Gynecol Oncol Rep. 2017 Mar 3;20:58-61. doi: 10.1016/j.gore.2017.02.011. eCollection 2017 May.

19.

Considerations for HPV primary screening in lower-middle income countries.

Maza M, Gage JC.

Prev Med. 2017 May;98:39-41. doi: 10.1016/j.ypmed.2016.12.029. Epub 2017 Feb 6.

PMID:
28279262
20.

Scale-Up of an Human Papillomavirus Testing Implementation Program in El Salvador.

Cremer M, Maza M, Alfaro K, Morales Velado M, Felix J, Castle PE, Kim J, Gage JC.

J Low Genit Tract Dis. 2017 Jan;21(1):26-32. doi: 10.1097/LGT.0000000000000280.

21.

Genotyping for Human Papillomavirus Types 16 and 18 in Women With Minor Cervical Lesions: A Systematic Review and Meta-analysis.

Arbyn M, Xu L, Verdoodt F, Cuzick J, Szarewski A, Belinson JL, Wentzensen N, Gage JC, Khan MJ.

Ann Intern Med. 2017 Jan 17;166(2):118-127. doi: 10.7326/M15-2735. Epub 2016 Nov 15. Review.

PMID:
27842420
22.

Similar Risk Patterns After Cervical Screening in Two Large U.S. Populations: Implications for Clinical Guidelines.

Gage JC, Hunt WC, Schiffman M, Katki HA, Cheung LA, Myers O, Cuzick J, Wentzensen N, Kinney W, Castle PE, Wheeler CM; New Mexico HPV Pap Registry Steering Committee.

Obstet Gynecol. 2016 Dec;128(6):1248-1257.

23.

The population impact of human papillomavirus/cytology cervical cotesting at 3-year intervals: Reduced cervical cancer risk and decreased yield of precancer per screen.

Silver MI, Schiffman M, Fetterman B, Poitras NE, Gage JC, Wentzensen N, Lorey T, Kinney WK, Castle PE.

Cancer. 2016 Dec 1;122(23):3682-3686. doi: 10.1002/cncr.30277. Epub 2016 Sep 22.

24.

A cohort study of cervical screening using partial HPV typing and cytology triage.

Schiffman M, Hyun N, Raine-Bennett TR, Katki H, Fetterman B, Gage JC, Cheung LC, Befano B, Poitras N, Lorey T, Castle PE, Wentzensen N.

Int J Cancer. 2016 Dec 1;139(11):2606-15. doi: 10.1002/ijc.30375. Epub 2016 Aug 26.

25.

Corrigendum to "A comparison of cervical histopathology variability using whole slide digitized images versus glass slides: experience with a statewide registry" [HumAN PatholOGY 2013;44:2542-2548].

Gage JC, Joste N, Ronnett BM, Stoler M, Hunt WC, Schiffman M, Wheeler CM.

Hum Pathol. 2016 Jun;52:201. doi: 10.1016/j.humpath.2016.04.001. Epub 2016 May 1. No abstract available.

26.

Comparison of Colposcopic Impression Based on Live Colposcopy and Evaluation of Static Digital Images.

Liu AH, Gold MA, Schiffman M, Smith KM, Zuna RE, Dunn ST, Gage JC, Walker JL, Wentzensen N.

J Low Genit Tract Dis. 2016 Apr;20(2):154-61. doi: 10.1097/LGT.0000000000000194.

27.

Introducing a High-Risk HPV DNA Test Into a Public Sector Screening Program in El Salvador.

Cremer ML, Maza M, Alfaro KM, Kim JJ, Ditzian LR, Villalta S, Alonzo TA, Felix JC, Castle PE, Gage JC.

J Low Genit Tract Dis. 2016 Apr;20(2):145-50. doi: 10.1097/LGT.0000000000000188.

28.

World Health Organization Guidelines for treatment of cervical intraepithelial neoplasia 2-3 and screen-and-treat strategies to prevent cervical cancer.

Santesso N, Mustafa RA, Schünemann HJ, Arbyn M, Blumenthal PD, Cain J, Chirenje M, Denny L, De Vuyst H, Eckert LO, Forhan SE, Franco EL, Gage JC, Garcia F, Herrero R, Jeronimo J, Lu ER, Luciani S, Quek SC, Sankaranarayanan R, Tsu V, Broutet N; Guideline Support Group.

Int J Gynaecol Obstet. 2016 Mar;132(3):252-8. doi: 10.1016/j.ijgo.2015.07.038. Epub 2015 Dec 14.

PMID:
26868062
29.

Risk assessment to guide cervical screening strategies in a large Chinese population.

Zhao FH, Hu SY, Zhang Q, Zhang X, Pan QJ, Zhang WH, Gage JC, Wentzensen N, Castle PE, Qiao YL, Katki HA, Schiffman M.

Int J Cancer. 2016 Jun 1;138(11):2639-47. doi: 10.1002/ijc.30012. Epub 2016 Feb 4.

30.

Risk Stratification Using Human Papillomavirus Testing among Women with Equivocally Abnormal Cytology: Results from a State-Wide Surveillance Program.

Gage JC, Hunt WC, Schiffman M, Katki HA, Cheung LC, Cuzick J, Myers O, Castle PE, Wheeler CM; New Mexico HPV Pap Registry Steering Committee.

Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):36-42. doi: 10.1158/1055-9965.EPI-15-0669. Epub 2015 Oct 30.

31.

Factors affecting attendance to cervical cancer screening among women in the Paracentral Region of El Salvador: a nested study within the CAPE HPV screening program.

Alfaro KM, Gage JC, Rosenbaum AJ, Ditzian LR, Maza M, Scarinci IC, Miranda E, Villalta S, Felix JC, Castle PE, Cremer ML.

BMC Public Health. 2015 Oct 16;15:1058. doi: 10.1186/s12889-015-2360-7.

32.

A study of HPV typing for the management of HPV-positive ASC-US cervical cytologic results.

Schiffman M, Vaughan LM, Raine-Bennett TR, Castle PE, Katki HA, Gage JC, Fetterman B, Befano B, Wentzensen N.

Gynecol Oncol. 2015 Sep;138(3):573-8. doi: 10.1016/j.ygyno.2015.06.040. Epub 2015 Jul 4.

33.

The Role of Human Papillomavirus Genotyping in Cervical Cancer Screening: A Large-Scale Evaluation of the cobas HPV Test.

Schiffman M, Boyle S, Raine-Bennett T, Katki HA, Gage JC, Wentzensen N, Kornegay JR, Apple R, Aldrich C, Erlich HA, Tam T, Befano B, Burk RD, Castle PE.

Cancer Epidemiol Biomarkers Prev. 2015 Sep;24(9):1304-10. doi: 10.1158/1055-9965.EPI-14-1353. Epub 2015 Jun 18.

34.

The Value of Endocervical Curettage in Addition to Biopsies in Women Referred to Colposcopy.

van der Marel J, Rodriguez A, Del Pino M, van Baars R, Jenkins D, van de Sandt MM, Torné A, Ordi J, ter Harmsel B, Verheijen RH, Schiffman M, Gage JC, Quint WG, Wentzensen N.

J Low Genit Tract Dis. 2015 Oct;19(4):282-7. doi: 10.1097/LGT.0000000000000124.

PMID:
26083332
35.

The comparative and cost-effectiveness of HPV-based cervical cancer screening algorithms in El Salvador.

Campos NG, Maza M, Alfaro K, Gage JC, Castle PE, Felix JC, Cremer ML, Kim JJ.

Int J Cancer. 2015 Aug 15;137(4):893-902. doi: 10.1002/ijc.29438. Epub 2015 Feb 3.

36.

Response.

Gage JC, Schiffman M, Katki HA, Castle PE, Fetterman B, Wentzensen N, Poitras NE, Lorey T, Cheung LC, Kinney WK.

J Natl Cancer Inst. 2014 Dec 26;107(1):390. doi: 10.1093/jnci/dju390. Print 2015 Jan. No abstract available.

37.

A study of genotyping for management of human papillomavirus-positive, cytology-negative cervical screening results.

Schiffman M, Burk RD, Boyle S, Raine-Bennett T, Katki HA, Gage JC, Wentzensen N, Kornegay JR, Aldrich C, Tam T, Erlich H, Apple R, Befano B, Castle PE.

J Clin Microbiol. 2015 Jan;53(1):52-9. doi: 10.1128/JCM.02116-14. Epub 2014 Oct 22.

38.

Age-stratified 5-year risks of cervical precancer among women with enrollment and newly detected HPV infection.

Gage JC, Katki HA, Schiffman M, Fetterman B, Poitras NE, Lorey T, Cheung LC, Castle PE, Kinney WK.

Int J Cancer. 2015 Apr 1;136(7):1665-71. doi: 10.1002/ijc.29143. Epub 2014 Sep 2.

39.

The low risk of precancer after a screening result of human papillomavirus-negative/atypical squamous cells of undetermined significance papanicolaou and implications for clinical management.

Gage JC, Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Behrens C, Sharma A, Zhao FH, Cuzick J, Yang ZH, Kinney WK.

Cancer Cytopathol. 2014 Nov;122(11):842-50. doi: 10.1002/cncy.21463. Epub 2014 Jul 9.

40.

Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test.

Gage JC, Schiffman M, Katki HA, Castle PE, Fetterman B, Wentzensen N, Poitras NE, Lorey T, Cheung LC, Kinney WK.

J Natl Cancer Inst. 2014 Jul 18;106(8). pii: dju153. doi: 10.1093/jnci/dju153. Print 2014 Aug.

41.

Analytic and clinical performance of cobas HPV testing in anal specimens from HIV-positive men who have sex with men.

Wentzensen N, Follansbee S, Borgonovo S, Tokugawa D, Sahasrabuddhe VV, Chen J, Lorey TS, Gage JC, Fetterman B, Boyle S, Sadorra M, Tang SD, Darragh TM, Castle PE.

J Clin Microbiol. 2014 Aug;52(8):2892-7. doi: 10.1128/JCM.03517-13. Epub 2014 Jun 4.

42.

Acceptability of self-collected versus provider-collected sampling for HPV DNA testing among women in rural El Salvador.

Rosenbaum AJ, Gage JC, Alfaro KM, Ditzian LR, Maza M, Scarinci IC, Felix JC, Castle PE, Villalta S, Miranda E, Cremer ML.

Int J Gynaecol Obstet. 2014 Aug;126(2):156-60. doi: 10.1016/j.ijgo.2014.02.026. Epub 2014 May 2.

PMID:
24880188
43.

A comparison of cervical histopathology variability using whole slide digitized images versus glass slides: experience with a statewide registry.

Gage JC, Joste N, Ronnett BM, Stoler M, Hunt WC, Schiffman M, Wheeler CM.

Hum Pathol. 2013 Nov;44(11):2542-8. doi: 10.1016/j.humpath.2013.06.015. Epub 2013 Sep 25.

44.

Plasma cytokine levels and human papillomavirus infection at the cervix in rural Nigerian women.

Mbulaiteye SM, Kemp T, Gage JC, Ajenifuja KO, Kiruthu C, Wentzensen NA, Adepiti C, Wacholder S, Burk RD, Schiffman M, Pinto L.

Cytokine. 2013 Oct;64(1):146-51. doi: 10.1016/j.cyto.2013.07.028. Epub 2013 Aug 22.

45.

Risk factors for anal HPV infection and anal precancer in HIV-infected men who have sex with men.

Schwartz LM, Castle PE, Follansbee S, Borgonovo S, Fetterman B, Tokugawa D, Lorey TS, Sahasrabuddhe VV, Luhn P, Gage JC, Darragh TM, Wentzensen N.

J Infect Dis. 2013 Dec 1;208(11):1768-75. doi: 10.1093/infdis/jit374. Epub 2013 Aug 1.

46.

Risk of precancer determined by HPV genotype combinations in women with minor cytologic abnormalities.

Gage JC, Schiffman M, Solomon D, Wheeler CM, Gravitt PE, Castle PE, Wentzensen N.

Cancer Epidemiol Biomarkers Prev. 2013 Jun;22(6):1095-101. doi: 10.1158/1055-9965.EPI-12-1455. Epub 2013 Apr 19.

47.

Five-year risk of recurrence after treatment of CIN 2, CIN 3, or AIS: performance of HPV and Pap cotesting in posttreatment management.

Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Raine-Bennett T, Gage JC, Kinney WK.

J Low Genit Tract Dis. 2013 Apr;17(5 Suppl 1):S78-84. doi: 10.1097/LGT.0b013e31828543c5.

48.

Follow-up testing after colposcopy: five-year risk of CIN 2+ after a colposcopic diagnosis of CIN 1 or less.

Katki HA, Gage JC, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Raine-Bennett T, Kinney WK.

J Low Genit Tract Dis. 2013 Apr;17(5 Suppl 1):S69-77. doi: 10.1097/LGT.0b013e31828543b1.

49.

Five-year risk of CIN 3+ to guide the management of women aged 21 to 24 years.

Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Raine-Bennett T, Gage JC, Kinney WK.

J Low Genit Tract Dis. 2013 Apr;17(5 Suppl 1):S64-8. doi: 10.1097/LGT.0b013e3182854399.

50.

Five-year risks of CIN 3+ and cervical cancer among women who test Pap-negative but are HPV-positive.

Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Raine-Bennett T, Gage JC, Kinney WK.

J Low Genit Tract Dis. 2013 Apr;17(5 Suppl 1):S56-63. doi: 10.1097/LGT.0b013e318285437b.

Supplemental Content

Support Center